Chronic Pain – Unmet Need – Detailed, Expanded Analysis | Fibromyalgia (US/EU)
Fibromyalgia is a chronic condition characterized by pain and tenderness. The primary goal of treatment is to reduce pain, and there are multiple well-established treatment options available, many of which are generic. Even though the majority of the diagnosed fibromyalgia population receives prescription drug treatment, most current therapies suffer from shortcomings in efficacy. The substantial percentage of patients with inadequate pain relief, the need for improved treatment of the secondary symptoms of fibromyalgia (e.g., anxiety, major depressive disorder, fatigue), and other areas with large unmet need (e.g., drugs that restore neuronal function)together pose ample commercial opportunity for new drugs that improve fibromyalgia treatment.
QUESTIONS ANSWERED
- What are surveyed rheumatologists’ opinions of the relative performance of select therapies, including Savella/Ixel/Milnaneurax (Allergan/Pierre Fabre/Neuraxpharm), Cymbalta/Xeristar (Eli Lilly/Boehringer Ingelheim), and Lyrica (Pfizer), on key efficacy, safety/tolerability, and convenience of administration attributes?
- What are the top areas of unmet need and opportunity in fibromyalgia?
- Based on the responses of surveyed physicians, what level of unmet need exists for key drug performance attributes?
- What trade-offs in drug price and drug performance across key drug attributes are surveyed rheumatologists willing to make?
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European rheumatologists fielded in January 2019.
Key companies: Allergan, Boehringer Ingelheim, Eli Lilly, Grünenthal, Janssen, Neuraxpharm, Pfizer, Pierre Fabre.
Key drugs: Duloxetine (Cymbalta/Xeristar, generics), gabapentin (Neurontin, generics), pregabalin (Lyrica, generics), milnacipran (Savella/Ixel, generics), tramadol (Ultram/Topalgic/Contramal/Tramal/Tramacet/Zydol, other brands, generics), amitriptyline, and cyclobenzaprine.
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Table of contents
- Chronic Pain - Unmet Need - Detailed, Expanded Analysis | Fibromyalgia (US/EU)
- 2019 TPP Simulator for Fibromylgia
- Introduction
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Rheumatologists' Prescribing Decisions in Fibromyalgia
- Importance of Efficacy Attributes to Prescribing Decisions in Fibromyalgia: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Fibromyalgia: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Fibromyalgia: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Fibromyalgia: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Fibromyalgia: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Fibromyalgia: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Fibromyalgia: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Fibromyalgia: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Fibromyalgia: United States
- Overall Performance of Key Therapies for Fibromyalgia: Europe
- Mean Overall Performance of Key Therapies for Fibromyalgia: United States and Europe
- Relative Performance of Key Therapies for Fibromyalgia Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for Fibromyalgia Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Fibromyalgia Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for Fibromyalgia Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for Fibromyalgia Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Fibromyalgia Across Select Convenience of Administration Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in Fibromyalgia
- Surveyed Rheumatologistsu2019 Satisfaction with the Performance of Key Therapies for Fibromyalgia on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Rheumatologistsu2019 Satisfaction with the Performance of Key Therapies for Fibromyalgia on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Fibromyalgia: United States
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Fibromyalgia: Europe
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Fibromyalgia: United States
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Fibromyalgia: Europe
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Fibromyalgia: United States
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Fibromyalgia: Europe
- Key Findings: Unmet Need in Fibromyalgia and Related Indications
- Surveyed Rheumatologists' Ascribed Level of Unmet Need in Fibromyalgia and Related Indications: United States
- Surveyed Rheumatologists' Ascribed Level of Unmet Need in Fibromyalgia and Related Indications: Europe
- Opportunity Analysis
- Target Product Profiles
- Appendix
Audreza Das, P.G. Dip., B.E., is a senior analyst on the CNS/Ophthalmology Disorders team at DRG, part of Clarivate. She has authored content on neuropathic pain, age-related macular degeneration, attention-deficit/hyperactivity disorder, unipolar depression, bipolar disorder, treatment-related depression, postherpetic neuralgia, painful diabetic neuropathy, and migraine. Ms. Das obtained her P.G. Dip. in cancer immunology and biotechnology from the University of Nottingham and a B.E. in biotechnology from the Birla Institute of Technology.